Bicycle Therapeutics
Yahoo Finance • 9 months ago
15 Small-Cap Stocks with High Potential
In this article, we will take a look at the 15 small-cap stocks with high potential. To skip our analysis of the latest trends, and market activity, you can go directly to see the 5 Small-Cap Stocks with High Potential. Nearly 9,500 stock... Full story
Yahoo Finance • last year
Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director
EDINBURGH and CAMBRIDGE, United Kingdom, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has appointed Kevin Lee Ph.D., MBA as Independent Non-Executive Director. Based in the UK... Full story
Yahoo Finance • last year
Bicycle Therapeutics and Orano Med Present Preclinical Bicycle® Radio-Conjugate Data at TIDES 2023
CAMBRIDGE, England & BOSTON & PARIS, May 11, 2023--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC) and Orano Med, two biotechnology companies respectively, announce pre-clinical results. Bicycle is pioneering a new and differentia... Full story
Yahoo Finance • 2 years ago
Bicycle Therapeutics Announces Collaboration With the German Cancer Research Center, to Discover and Develop Wholly Owned Bicycle® Radio Conjugates for a Range of Oncology Targets
CAMBRIDGE, England, & BOSTON, May 04, 2023--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) te... Full story
Yahoo Finance • 2 years ago
Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium
- Company to Host Conference Call on February 14 at 8:00 a.m. ET - CAMBRIDGE, England, & BOSTON, January 11, 2023--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class... Full story
Yahoo Finance • 2 years ago
Bicycle Therapeutics Announces Publication of Article in the Journal of Medicinal Chemistry Highlighting Preclinical Data from BT8009 Program
CAMBRIDGE, England & BOSTON, October 10, 2022--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®)... Full story
Yahoo Finance • 2 years ago
Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
- Continued clinical progress across pipeline, including dosing of the first patient in expansion cohorts of Phase I/II study of BT5528 - Expansion of Genentech exclusive strategic collaboration, triggering a $10 million payment to Bicycl... Full story
Yahoo Finance • 2 years ago
Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Associated with EphA2 Expression
Completed Phase I dose escalation; results expected in 3Q22 CAMBRIDGE, England & BOSTON, June 08, 2022--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therape... Full story
Yahoo Finance • 3 years ago
Analysts Are Downgrading These 10 Pharmaceutical Stocks
In this article, we present the 10 pharmaceutical stocks that are being downgraded by analysts. You can skip our analysis of the pharmaceutical industry and go directly to Analysts Are Downgrading These 5 Pharmaceutical Stocks. The pharma... Full story
